Welcome to our dedicated page for SS INNOVATIONS INTL news (Ticker: SSII), a resource for investors and traders seeking the latest updates and insights on SS INNOVATIONS INTL stock.
SS Innovations International, Inc (SSII) was founded by a seasoned leadership team with vast experience in medical research, innovation, and development in the medical robotics sector. The company aims to meet the rising demand for practical medical robotic devices by creating a platform-independent precision guidance system, initially focusing on skin resurfacing.
The flagship SSi Mantra surgical device has been utilized in over 1000 procedures, showcasing the company's commitment to advancing robotic surgery. Dr. Sudhir Srivastava, the Chairman and CEO of SS Innovations, highlights the Mantra's fifth arm capability, enabling complex cardiac surgeries with minimal invasiveness, reduced blood loss, quicker recovery times, and superior outcomes.
The global market for cardiac surgery devices and surgical robotics is growing rapidly, presenting significant opportunities for SS Innovations. The Company's innovative approach and unique value proposition position it well for future success and market expansion.
SS Innovations International, Inc. (OTC: SSII) has announced the addition of Tim Adams to its Board of Directors as an Independent Director. Mr. Adams, a healthcare executive with over 40 years of experience, currently serves as a Regional Operating Officer at Ascension, overseeing high-growth Horizontal Business Units. His extensive background includes leadership roles at major healthcare providers such as Tenet Healthcare , Community Health Systems, and HCA.
Dr. Sudhir Srivastava, SS Innovations Chairman and CEO, expressed enthusiasm about Mr. Adams joining during a phase of global growth. The company recently launched the SSI Mantra 3, an advanced surgical robotic system designed for multi-specialty usage. SS Innovations is currently seeking FDA approval and anticipates receiving marketing approval in the second half of 2025.
SS Innovations International, Inc. (OTC: SSII) has announced a significant milestone: over 2,000 successful robotic surgeries performed using its SSi Mantra Surgical Robotic System, primarily in India. This achievement underscores the company's commitment to making advanced surgical technologies accessible globally.
The SSi Mantra system has been praised for its ergonomic design and precise controls, facilitating minimally invasive procedures and improving patient outcomes. It has been installed in numerous Tier 2 and Tier 3 cities across India, as well as in Nepal, marking the country's first surgical robot.
Of the 2,000 surgeries, 123 were cardiac cases, demonstrating the system's versatility. The company's focus on 'democratizing access' and 'decentralizing excellence' in healthcare is evident in its efforts to make world-class robotic surgery affordable and accessible to a larger global population.
SS Innovations International, Inc. (OTC: SSII) has provided an update on its progress towards FDA approval for the SSi Mantra Surgical Robotic System. The company completed its first interactive pre-submission meeting with the FDA earlier this year and received valuable feedback. Based on this, SSII will proceed with a de novo pathway for pre-market submission for numerous indications in parallel.
SSII plans to submit an investigational device exemption (IDE) application in Q1 2025 to initiate clinical trials for various indications including abdominal, pelvis, thoracic, and cardiac procedures. The company expects to secure pre-market approvals by the end of 2025. SSII believes it can meet clinical trial requirements quickly due to the SSi Mantra's demonstrated safety and efficacy in India, where it has already performed all types of surgical procedures for which approval is being sought.
SS Innovations International (OTC: SSII) has announced the addition of Dr. Fredric Moll to its Board of Directors as Vice Chairman. Dr. Moll, known as the 'father of surgical robotics', brings extensive industry experience as the founder of Intuitive Surgical and developer of the da Vinci surgical robotic system. He recently served as Chief Development Officer for Johnson & Johnson Medical Devices Companies and was co-founder and CEO of Auris Health.
SS Innovations recently launched the SSI Mantra 3, an advanced surgical robotic system designed for multi-specialty usage. The company is currently seeking FDA approval, expected in late 2025. Dr. Moll's appointment comes at a time of global growth for SS Innovations, with the company aiming to make robotic surgery more affordable and accessible worldwide.
SS Innovations International, Inc. (OTC: SSII) has announced its first sale of the SSi Mantra Surgical Robotic System in South America, specifically in Ecuador. The company received regulatory approval for clinical use in Ecuador in May 2024 and partnered with Ingemedica Del Ecuador S.A. for distribution. The first system will be installed at Interhospital in Guayaquil City, Ecuador.
The SSi Mantra system aims to make robotic surgery affordable and accessible globally. It has been used in over 1,900 cases across 80+ surgical procedures and has received regulatory approvals in India, Indonesia, Nepal, Guatemala, and now Ecuador. SS Innovations is also seeking approvals in the US and EU, expected in the second half of 2025.
SS Innovations International (OTC: SSII), a developer of surgical robotic technologies, has issued an update on its audit process and trading status. The company's previous auditor, BF Borgers CPA PC, was barred by the SEC, leading to the appointment of BDO India as the new auditor. SSII is undergoing a reaudit of its financial statements for 2022 and 2023, along with an internal review of accounting policies and controls.
Due to delayed filings, SSII's stock has been moved to the Expert Market Tier with liquidity. The company is working to complete the reaudit and become current with SEC reporting to restore its OTC Pink Tier status. Despite these challenges, SSII's operations and growth remain unaffected. The company recently added two experienced independent directors to its board and continues to develop its SSi Mantra surgical robotic system.
SS Innovations International, Inc. (OTC: SSII) is set to unveil its latest innovation in robotic surgery, the SSi Mantra-3 Surgical Robotic System, in New York City. This groundbreaking system, capable of featuring up to 5 robotic arms, will be demonstrated from July 23rd to 25th at the company's new showroom in the financial district. A live stream webcast will also be available on July 23rd for remote viewing.
The event will showcase the system's capabilities and offer insights into the future of surgical robotics. Key opinion leaders, including Dr. Frederic Moll and Dr. Vipul Patel, will be present to discuss the impact of the SSi Mantra-3. SS Innovations aims to make robotic surgery more affordable and accessible globally, with the SSi Mantra system already approved in India and undergoing regulatory processes in the US and EU.
SS Innovations International announced the installation of its SSi Mantra Surgical Robotic System at B&B Hospital in Kathmandu, Nepal, marking the first surgical robot in the country. This collaboration aims to enhance healthcare standards by providing advanced surgical options. The SSi Mantra system, known for its precision and minimally invasive capabilities, promises improved patient outcomes and faster recovery times. CEO Dr. Vishwa Srivastava expressed pride in making this technology accessible to Nepal. The hospital's leadership highlighted the potential for significant enhancements in patient care, positioning B&B Hospital as a regional leader in medical innovation.
SS Innovations International (OTC: SSII) has been named a finalist for the 'Outstanding Company' category at the Surgical Robotics Industry Awards 2024. The company’s SSi Mantra Surgical Robotic System is operational in 40 hospitals in India and at Johns Hopkins University Hospital's MISTIC center for clinical training. Other finalists include industry leaders like Intuitive and Medtronic. The awards, held in partnership with Novanta, will be announced on June 26, 2024. CEO Dr. Sudhir Srivastava highlighted the company's growth, including completing 100 robotic cardiac surgeries. The company is pursuing regulatory approvals in the US and EU, expecting FDA and CE Mark approvals in 2025.
SS Innovations International has received regulatory approval from the Indonesian Ministry of Health for its SSi Mantra Surgical Robotic System, enabling clinical use in Indonesia. This approval marks a significant milestone for SS Innovations as it aims to make robotic surgeries more affordable and accessible globally. Indonesia, with over 279 million people, has seen slow adoption of robotic surgery, with only 700 procedures completed since 2012. SS Innovations plans to increase access and decrease costs of robotic surgery in Indonesia. The SSi Mantra, the first surgical robotic system made in India, is clinically validated for over 70 types of surgeries and has completed 100 robotic cardiac surgeries in a year. The company is also seeking regulatory approval in the US and EU, with anticipated approvals in 2025.
FAQ
What is the current stock price of SS INNOVATIONS INTL (SSII)?
What is the market cap of SS INNOVATIONS INTL (SSII)?
What is SS Innovations International, Inc's core focus?
How many procedures have used SS Innovations' flagship device?
What differentiates the SSi Mantra surgical device in the market?
What market trends support SS Innovations' growth?
Who is Dr. Sudhir Srivastava and what is his role at SS Innovations?
What is the projected growth rate of the global surgical robotics market?
How does SS Innovations plan to enhance its market position?
What recent milestone did SS Innovations achieve with the SSi Mantra device?
What is SS Innovations' competitive advantage in the medical robotics field?
How does SS Innovations plan to uplist its common stock to a National Securities Exchange?
